

# Select the Colorectal Cancer (CRC) test that's right for your patient.

Water-and blood-based collection methods are available from Sonora Quest Laboratories.

## InSure® | Fecal Globin by Immunochemistry Test

FIT testing is now easier than ever with InSure ONE.<sup>1</sup> A study has confirmed substantially equivalent test performance can be achieved with ONE collection of stool. Greater convenience may equal improved screening outcomes.<sup>2</sup>

Your patient collects a water-based sample in the privacy of his or her home, with no direct fecal handling required and no dietary or medicinal restrictions, making screening with InSure ONE convenient and compliant.<sup>3,4</sup>



### InSure ONE is easier to use

It is the only FIT test that is performed using toilet water samples from one bowel movement.

- NO stool collection or handling of feces required.
- There are no dietary or medicinal restrictions.
- Simple brush collection method shown to increase patient compliance by 66%.<sup>2</sup>

Please see instruction card included with kit for full instructions.

### InSure ONE is accurate

- Detects blood in fecal samples, which may be an indication of lower gastrointestinal bleeding that can be associated with disorders, such as diverticulitis, ulcerative colitis, polyps, colorectal cancers, or large adenomas that bleed.
- InSure ONE reliably detects 50ug Hb/g feces, in at least 95% positive readings.<sup>4</sup>
- FIT testing is supported by medical guidelines, including the American Cancer Society, the American College of Gastroenterology, and the U.S. Preventive Services Task Force for early detection of Colorectal Cancer.<sup>5,6,7</sup>

## ColoVantage® | Methylated Septin 9 Blood Test

ColoVantage is a simple blood test that detects methylated Septin 9, an epigenetic biomarker specific for CRC. Now you can offer a new, convenient CRC detection method for patients who are non-adherent to current testing modalities. With a positive result, you and your patient have the insight needed to evaluate the next steps, such as a colonoscopy or further evaluation.<sup>7,8,12</sup>



### ColoVantage is convenient

- A plasma-based blood test, ColoVantage is easily added to routine blood work.
- No patient preparation, such as fasting, is required before testing.
- No need for at-home patient sample collection/return procedures.

### ColoVantage is innovative and effective

- ColoVantage detects methylated Septin 9, an epigenetic marker specific for CRC, with 99.9% negative predictive value.<sup>7</sup>
- Septin 9 is a valuable biomarker that offers patients and caregivers an innovative blood test that can help detect CRC and potentially help save lives.
- In a clinical validation study, ColoVantage achieved 70% sensitivity and 89% specificity overall.<sup>8,9</sup>

## The more you know, the more you can do

Colorectal cancer (CRC) is still the second leading cause of cancer death among men and women in the United States,<sup>10</sup> even though it's well-accepted that the majority of CRC can be prevented through annual screening and detection. CRC screening can reduce deaths both by preventing the disease, and by detecting it earlier, when treatment is more effective.<sup>10</sup> When CRC is diagnosed at an early versus late-stage, 5-year survival increases from 12.5% to 90%.<sup>11</sup> Accurate CRC screening and detection is the first step in prevention.

Even so, many patients still ignore a potentially life-saving screening because they believe it's too invasive, uncomfortable, or inconvenient, and compliance remains a challenge.<sup>12</sup>

## Test ordering information

Test Name	Test Code	CPT Code(s)	Specimen Requirements	Turnaround Time**
InSure® Fecal Globin by Immunochemistry	11290 11293 (Medicare screen)	82274 G0328	A long-handled brush is used to collect and transfer a small amount of the water from one bowel movement to the InSure ONE test card. <sup>4</sup>	24 hours after receipt by testing laboratory
ColoVantage® (methylated Septin 9)	904413	81327	10 mL frozen EDTA plasma (lavender top) tube; 5 mL minimum	5 days

\* The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed. \*\*Approximate

## References

1. Cole SR, et al. DDW Abstract. 2009.
2. Cole SR, Young GP, Esterman A, Cadd B, Morcom JA. Randomized trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer. *J Med Screen.* 2003;10:117-122
3. InSure® FIT K002457-Instructions for Use (IFU).
4. InSure® ONE™ Fecal Immunochemistry Test Immunoassay for human hemoglobin in stool. Product Instructions. Enterix, Inc. Edison, NJ. 2017.
5. U.S. Preventive Services Task Force. [www.uspreventiveservicestaskforce.org/uspstf/uspscolo.gtm](http://www.uspreventiveservicestaskforce.org/uspstf/uspscolo.gtm). Accessed Nov 2, 2017.
6. The American Journal of Gastroenterology, Gastroenterology, and GIE: Gastrointestinal Endoscopy. Published June 6, 2017.
7. Lieberman DA. Screening for colorectal cancer. *N Engl J Med.* 2009;361:1179-1187
8. Data on file at Quest Diagnostics. Does not replace colonoscopy, which at >95% sensitivity and 90% specificity, should be offered first when medically possible.
9. Results of a clinical validation study (n=252), which detected CRC in all stages. The number of patients at each stage was too small to derive stage-specific sensitivity data.
10. American Cancer Society. Cancer Prevention & Early Detection Facts & Figures 2017. American Cancer Society. 2017.
11. National Cancer Institute SEER (Surveillance, Epidemiology, and End Results Program). SEER Stat Fact Sheets: Colon and Rectum Cancer. <http://seer.cancer.gov/statfacts/html/colorectal.html>. Accessed Nov 4, 2013.
12. deVos T, Tetzner R, Model F, et al. Circulating methylated SEPT( DNA in plasma is a biomarker for colorectal cancer). *Clinical Chemistry.* 2009;55:1337-1346
13. Rex DK, et al. U.S. MSTF Consensus Guideline Gastroenterology. 2017;153:307-323
14. InSure® ONE™ Fecal Immunochemistry Test Immunoassay for human hemoglobin in stool. Patient Instructions. Enterix, Inc. Edison, NJ. 2017.
15. Smith A, Young GP, Cole SR, Bampton P. Comparison of a brush-sampling fecal immunochemistry test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. *Cancer.* 2006;107:2152-2159.

\*The study was funded in part by Enterix Inc. (through Enterix Australia Pty Ltd), the manufacturer of InSure FIT. Neither Enterix nor Sonora Quest Laboratories participated in the data analysis or influenced the conclusions reached by the authors.

SonoraQuest.com

Sonora Quest Laboratories, any associated logos, and all associated Sonora Quest Laboratories registered or unregistered trademarks are the property of Sonora Quest Laboratories. All third-party marks—® and ™—are the property of their respective owners. © 2018 Sonora Quest Laboratories. All rights reserved. 3/2018

## Two patient-friendly solutions

We understand the importance of CRC-screening and recognize that compliance has been shown to increase significantly with simplified CRC-screening methods.<sup>2</sup> That's why we offer 2 screening and detection choices to address your patients' concerns—InSure®, a fecal immunochemical test, and ColoVantage®, a convenient blood test.

**Sonora Quest Laboratories offers you and your patients a choice of 2 patient-friendly tests for CRC screening and detection.**



Sonora Quest  
Laboratories™

A Subsidiary of Laboratory Sciences of Arizona